Full TitleA Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM (A032101) (CIRB)
The usual treatment for people with metastatic prostate cancer is hormonal therapy, including a medication to lower testosterone levels in the body and a potent oral hormonal medication to block growth signals from male hormones in cancer cells. Patients whose cancer is responding exceptionally well to this therapy may be able to take a break from these medications, with guidance from their doctors. The purpose of this study is to see if it is possible to interrupt antiandrogen therapy in people with metastatic hormone-sensitive prostate cancer that is responding very well to androgen receptor-pathway inhibitor therapy.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants in this study must have hormone-sensitive metastatic prostate cancer and be responding exceptionally well to hormonal therapy.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information about this study and to inquire about eligibility, please contact the office of Dr. Andrew Laccetti at 646-422-4683.